



PTO/SB/08A (09-08)

Approved for use through 03/31/2007. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/730,614
Filing Date	12/08/2003
First Named Inventor	Jun Li
Art Unit	1635
Examiner Name	GIBBS, Terra C.
Attorney Docket Number	9/263

Sheet 1 of 9

**U. S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
TCG		US- 2006/0073120	04-2006	Li, et al.	
		US- 2004/0014111	01/2004	Li, et al.	
		US- 6,395,545	05-28-2002	MONIA, B.P., et al.	
		US- 2002/0132788	09-19-2002	D. LEWIS, et al.	
		US- 2003/0170719 A1	09/11/2003	MATSUDA, et al.	
		US- 2003/0143540 A1	07/31/2003	MATSUDA, et al.	
		US- 6,235,513	05/22/2001	Mike ROTHE, et al.	
		US- 2003/0124726 A1	07/2003	De Fougerolles, et al.	
		US- 6,649,637	11-2003	CURIEL, T.	
		US- 6,258,579 B1	07-2001	MERCURIO, et al.	
TCG		US- 4,745,119	05-1988	KRENITSKY, T.A.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>4</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				

Examiner  
Signature

/Terra Cotta Gibbs/

Date

Considered

01/31/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-788-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/730,614		
		Filing Date	12/08/2003		
		First Named Inventor	Jun Li		
		Art Unit	1635		
		Examiner Name	GIBBS, Terra C.		
Sheet	2	of	9	Attorney Docket Number	9/263

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
TCG		PAHL, H.L., "Activators and Target Genes of Rel/NF-kB Transcription Factors", Oncogene, 1999, Vol. 18, pg 6853-6866	
		MERCURIO, F., et al. "NF-kB as a Primary Regulator of the Stress Response", Oncogene, 1999, Vol. 18, pg 6163-6171	
		BARKETT, M., et al. "Control of Apoptosis by Rel/NF-kB Transcription Factors", Oncogene, 1999, Vol. 18, pg 6910-6924	
		KARIN, M., "How NF-kB is activated: The Role of the Ikb Kinase (IKK) Complex", Oncogene, 1999, Vol. 18, pg 6867-6874	
		JIANG, M., et al. "Selective Silencing of Viral Gene Expression in HPV-Positive Human Cervical Carcinoma Cells Treated with siRNA, a Primer of RNA Interference", Oncogene, 2002, Vol. 21, pg 6041-6048	
		JOBIN, C., et al. "The Ikb/NF-kB System: A Key Determinant of Mucosal Inflammation and Protection", American Journal of Physiology, Cellular Physiology, Vol. 278, pg 451-462	2000
		SIEBENLIST, U., et al.; "Structure, Regulation and Function of NF-kappaB"; Annual Review of Cell Biology, November 1994, Vol. 10, Pages 405-455	
		BALDWIN, A., Jr., et al. "The NF-kB and Ikb Proteins: New Discoveries and Insights", Annual Review of Immunology, 1996, Vol. 14, pg. 649-681	
		GHOSH, S., et al., "NF-kB and Rel Proteins: Evolutionarily Conserved Mediators of Immune Responses", Annual Review of Immunology, 1998, Vol. 16, pg. 225-260	
TCG		LI, Z. W., et al. "The IKKb Subunit of Ikb Kinase (IKK) is Essential for Nuclear Factor kB Activation and Prevention of Apoptosis", Journal of Experimental Medicine, 1999, Vol. 189, No. 11, pg. 1839-1845	

Examiner Signature	/Terra Cotta Gibbs/	Date Considered	01/31/2007
--------------------	---------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number 10/730,614

Filing Date 12/08/2003

First Named Inventor Jun LI

Art Unit 1635

Examiner Name GIBBS, Terra C.

Sheet 3 of 9 Attorney Docket Number 9/263

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
TCG		LI, X., et al. "IKKa, IKKb, and NEMO/IKKy Are Each Required for the NF-kB-Mediated Inflammatory Response Program", The Journal of Biological Chemistry, 2002, Vol. 277, No. 47, pg. 45129-45140	
		HU, Y., et al. "Abnormal Morphogenesis But Intact IKK Activation in Mice Lacking the IKKa Subunit of Ikb Kinase", Science, 1999, Vol. 284, pg. 316-320	
		ANEST, V., et al. "A Nucleosomal Function for Ikb Kinase-a in NF-kB-dependent Gene Expression", Nature, 2003, Vol. 423, pg. 659-663	
		FIRE, A., et al. "Potent and Specific Genetic Interference by Double-Stranded RNA in Caenorhabditis Elegans", Nature, 1998, Vol. 391, pg. 806-811	
		ELBASHIR, S. M., et al. "Duplexes of 21-nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells", Nature, 2001, Vol. 411, pg. 494-498	
		HANNON, G. J., et al. "RNA Interference", Nature, 2002, Vol. 418, pg. 244-250	
		SHARP, P. A., et al. "siRNA-directed Inhibition of HIV-1 Infection", Nature Medicine, 2002, Vol. 8, pg. 681-687	
		IRIE, N., et al. "Subtype- and Species-Specific Knockdown of PKC using Short Interfering RNA", Biochemical and Biophysical Research Communications, 2002, Vol. 298, pg. 738-743	
		SHARP, P. A., "RNA Interference - 2001", Genes and Development, 2001, Vol. 15, pg.485-490	
TCG		MCMANUS, M.T., et al. "Small Interfering RNA-Mediated Gene Silencing in T Lymphocytes", Journal of Immunology, 2002, Vol. 169, pg. 5754-5760	

Examiner  
Signature

/Terra Cotta Gibbs/

Date  
Considered

01/31/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.87 and 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/730,614		
		Filing Date	12/08/2003		
		First Named Inventor	Jun Li		
		Art Unit	1635		
		Examiner Name	GIBBS, Terra C.		
Sheet	4	of	9	Attorney Docket Number	9/263

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
TCG		CHARLES A. PARKOS, et al. "Primary structure and unique expression of the 22-kilodalton light chain of human neutrophil cytochrome beta"; Proc. Natl. Acad. Sci. USA; Vol. 85, pp 3319-3323; 1988	
		FANG QIAN, et al. "The Structure of the Mouse Cathepsin B Gene and Its Putative Promoter"; DNA and CELL BIOLOGY, Vol. 10, No. 3, pp 159-168, 1991	
		MARK E. ROSENBERG, et al. "Clusterin: Physiologic and Pathophysiologic Considerations"; Int. J. Biochem. Cell. Biol., Vol. 27, No. 7, pp 633-645, 1995	
		YINLING HU, et al. "IKKalpha controls formation of the epidermis independently of NF-kB"; NATURE, Vol. 410, pp710-714, 2001	
		AMER A. BEG, et al. "Embryonic Lethality and Liver Degeneration in Mice Lacking the RelA Component of NF-kB"; NATURE; Vol. 376; pp 167-170, 1995	
		ROBYN STARR, et al. "A Family of Cytokine-Inducible Inhibitors of Signalling"; NATURE, Vol. 387, pp. 917-921, 1997	
		MARY C. DINAUER, et al. "Human Neutrophil Cytochrome b Light Chain (p22-phox)" J. Clin. Invest. Vol. 86, pp 1729-1737, 1990	
		JOHN R. SILKENSEN, et al. "The Role of Clusterin in Tissue Injury", Biochem. Cell. Biol. Vol. 72, pp 483-488, 1994	
		CONSTANTIN MAKRIS, et al. "Femal Mice Heterozygous for IKK $\gamma$ /NEMO Deficiencies Develop a Dermatopathy Similar to the Human X-Linked Disorder Incontinentia Pigmenti"; Molecular Cell, Vol 5, pp 969-979, 2000	
TCG		MARC SCHMIDT-SUPPRIAN, et al. "NEMO/IKK $\gamma$ -Deficient Mice Model Incontinentia Pigmenti" Molecular Cell, Vol. 5, pp 981-992, 2000	

Examiner Signature	/Terra Cotta Gibbs/	Date Considered	01/31/2007
--------------------	---------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	10/730,614
		Filing Date	12/08/2003
		First Named Inventor	Jun Li
		Art Unit	1635
		Examiner Name	GIBBS, Terra C.
		Attorney Docket Number	9/263
Sheet	5	of	9

(Use as many sheets as necessary)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
TCG		YIXUE CAO, et al. "IKKalpha Provides an Essential Link between RANK Signaling and Cyclin D1 Expression during Mammary Gland Development", Cell, Vol. 107, pp 763-775, 2001	
		VIGO HEISSMEYER, et al. "Shared Pathways of Ikb Kinase-Induced SCF -Mediated Ubiquitination and Degradation for the NF-kB Precursor p105 and Ikbalpha", Mol. Cell. Biol. Vol. 21, No. 4, pp 1024-1035, 2001	
		MARK E. ROSENBERG, et al. "Apollipoprotein J/Clusterin Prevents a Progressive Glomerulopathy of Aging", Mol. Cell. Biol., Vol. 22, No. 6, pp 1893-1902, 2002	
		TOMMASO ZANOCCO-MARANI, et al. "Biological Activities and Signaling Pathways of the Granulin/Epithelin Precursor", Cancer Research, Vol. 59, pp 5331-5340, 1999	
		MINORU TANAKA, et al. "Reconstitution of the Functional Mouse Oncostatin M (OSM) Receptor: Molecular Cloning of the Mouse OSM Receptor Beta Subunit", Blood, Vol. 93, No. 3, pp 804-815, 1999	
		JOHN C. GROSKOPF, et al. "Proliferin Induces Endothelial Cell Chemotaxis through a G Protein-Coupled, Mitogen-Activated Protein Kinase-Dependent Pathway", Endocrinology, Vol 138, No. 7, pp 2835-2840, 1997	
		DANIEL J. TOFT, et al. "Reactivation of Proliferin gene expression is associated with increased angiogenesis in a cell culture model of fibrosarcoma tumor progression", PNAS, Vol. 98, No. 23, pp 13055-13059, 2001	
		STEVEN S. SMITH, et al. "Mechanism of Human Methyl-directed DNA methyltransferase and the fidelity of cytosine methylation", Proc. Natl. Acad. Sci. USA, Vol. 89, pp 4744-4748, 1992	
		YUJING LIU, et al. "Mouse model of G activator deficiency manifests cerebellar pathology and motor impairment", Proc. Natl. Acad. Sci. USA, Vol. 94, pp 8138-8143, 1997	
TCG		CHIARA BERLATO, et al. "Involvement of Suppressor of Cytokine Signaling-3 as a Mediator of the Inhibitory Effects of IL-10 on Lipopolysaccharide-Induced Macrophage Activation", The Journal of Immunology, Vol. 168, 6404-6411, 2002	

Examiner Signature	/Terra Cotta Gibbs/	Date Considered	01/31/2007
--------------------	---------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete If Known</b>			
		Application Number	10/730,614		
		Filing Date	12/08/2003		
		First Named Inventor	Jun Li		
		Art Unit	1635		
		Examiner Name	GIBBS, Terra C.		
Sheet	6	of	9	Attorney Docket Number	9/263

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
TCG		NORIO MATSUSHIMA, et al. "Super-Motifs and Evolution of Tandem Leucine-Rich Repeats Within the Small Proteoglycans-Biglycan, Decorin, Lumican, Fibromodulin, PRELP, Keratocan, Osteoadherin, Epiphygan, and Osteoglycin" PROTEINS Vol. 38; pp 210-225 2000	
		LEO W.J. KLOMP, et al. "Ceruloplasmin Gene Expression in the Murine Central Nervous System" J. Clin. Invest. Vol. 98, No. 1, pp 207-215 1998	
		NOBUAKI SHIMIZU, et al. "A Putative G Protein-Coupled Receptor, RDC1, Is a Novel Coreceptor for Human and Simian Immunodeficiency Viruses"; J. of Virology, Vol. 74, No. 2, pp 619-626, 2000	
		ROSEMARIE PANETTA, et al. "Regulators of G-Protein Signaling (RGS) 1 and 16 are Induced in Response to Bacterial Lipopolysaccharide and Stimulate c-fos Promoter Expression", Biochem. and Biophys. Research Comm., Vol. 259, pp 550-556, 1999	
		CAROL BEADLING, et al. "Regulators of G Protein Signaling Exhibit Distinct Patterns of Gene Expression and Target G Protein Specificity in Human Lymphocytes", J. Immunology, Vol. 162, pp 2677-2682, 1999	
		ULRICH BOEHM, et al. "Two Families of GTPases Dominate the Complex Cellular Response to IFN-γ1" J. Immunology, Vol. 161, pp 6715-6723, 1998	
		THOMAS A. WYNN, et al. "Identification and Characterization of a New Gene Family Induced During Macrophage Activation", J. Immunology, Vol. 147, No. 12, pp 4384-4392, 1991	
		DOROTHEA RUDOLPH, et al. "Severe liver degeneration and lack of NF-κB activation in NEMO/IKKγ-deficient mice" Genes and Development, Vol. 14, pp 854-862, 2000	
		SMITH, et al., Oral Use of Interferon-Alpha Stimulates ISG-15 Transcription and Production by Human Buccal Epithelial Cells", Journal of Interferon and Cytokine Research, 1999, Vol. 19, pp 923-928	
TCG		SEYMOUR KATZ, "Update In Medical Therapy of Ulcerative Colitis", Journal of Clinical Gastroenterology, 2002, Vol. 34, pp 397-407	

Examiner Signature	/Terra Cotta Gibbs/	Date Considered	01/31/2007
--------------------	---------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/730,614		
		Filing Date	12/08/2003		
		First Named Inventor	Jun Li		
		Art Unit	1635		
		Examiner Name	GIBBS, Terra C.		
Sheet	7	of	9	Attorney Docket Number	9/263

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
TCG		JUN LI, et al. "Recombinant IκB Kinases alpha and beta Are Direct Kinases of IκBα"; J. Biol. Chem., Vol. 273, No. 46, pp 30736-30741, 1998	
		MICHAEL J. MAY, et al. "Selective Inhibition of NF-κB Activation by a Peptide That Blocks the Interaction of NEMO with the IκB Kinase Complex"; SCIENCE, Vol 289, pp 1550-1554, 2000	
		QIUTANG LI, et al. "Severe Liver Degeneration in Mice Lacking the IκB Kinase 2 Gene"; SCIENCE, Vol. 284, pp 321-325, 1999	
		MIREILLE DELHASE, et al. "Positive and Negative Regulation of IκB Kinase Activity Through IKKB Subunit Phosphorylation"; SCIENCE, Vol. 284, pp 309-313, 1999	
		UWE SENFTLEBEN, et al. "Activation by IKKα of a Second, Evolutionary Conserved, NF-κB Signaling Pathway"; SCIENCE, Vol. 293, pp 1495-1499, 2001	
		YUMI YAMAMOTO, et al. "IKKγ/NEMO Facilitates the Recruitment of the IκB Proteins into the IκB Kinase Complex"; J. Biol. Chem., Vol. 276, No. 39, pp 36327-36336, 2001	
		JUN LI, et al. "Novel NEMO/IκB Kinase and NF-κB Target Genes at the Pre-B to Immature B Cell Transition"; J. Biol. Chem., Vol. 276, No. 21, pp 18579-18590, 2001	
		NYWANA SIZEMORE, et al. "Distinct Roles of the IκB Kinase alpha and beta Subunits in Liberating Nuclear Factor κB (NF-κB) from IκB and in Phosphorylating the p65 Subunit of NF-κB"; J. Biol. Chem. Vol. 277, No. 6, pp 3863-3869, 2000	
		YUJI SHIRAKATA, et al. "Epregulin, a Novel Member of the Epidermal Growth Factor Family, Is an Autocrine Growth Factor in Normal Human Keratinocytes"; J. Biol. Chem. Vol. 275, No. 8, pp 5748-5753, 2000	
TCG		BEVERLY ROTHERMEL, et al. "A Protein Encoded within the Down Syndrome Critical Region is Enriched in Striated Muscles and Inhibits Calcineurin Signaling"; J. Biol. Chem., Vol. 275, No. 12, pp 8719-8725, 2000	

Examiner Signature	/Terra Cotta Gibbs/	Date Considered	01/31/2007
--------------------	---------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete If Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	10/730,614		
		Filing Date	12/08/2003		
		First Named Inventor	Jun Li		
		Art Unit	1635		
		Examiner Name	GIBBS, Terra C.		
Sheet	8	of	9	Attorney Docket Number	9/263

(Use as many sheets as necessary)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
TCG		ANGELA R. ALDRED, et al. "Rat Ceruloplasmin: Molecular Cloning and Gene Expression in Liver, Choroid Plexus, Yolk Sac, Placenta, and Testis", J. Biol. Chem. Vol. 262, No. 6, pp 2875-2878, 1987	
		ERIK G. LUND, et al. "cDNA Cloning of Mouse and Human Cholesterol 25-Hydroxylases, Polytopic Membrane Proteins that Synthesize a Potent Oxysterol Regulator of Lipid Metabolism", J. Biol. Chem. Vol. 273, No. 51, pp 34316-34327, 1998	
		INIGO SANTAMARIA, et al. "Cathepsin Z, a Novel Human Cysteine Proteinase with a Short Propeptide Domain and a Unique Chromosomal Location", J. Biol. Chem. Vol. 273, No. 27, pp 16816-16823, 1998	
		INIGO SANTAMARIA, et al. "Molecular Cloning and Structural and Functional Characterization of Human Cathepsin F, a New Cysteine Proteinase of the Papain Family with a Long Propeptide Domain", J. Biol. Chem. Vol. 274, No. 20, pp 13800-13809, 1999	
		TSUNEYASU KAISHO, et al. "I $\kappa$ B Kinase $\alpha$ Is Essential for Mature B Cell Development and Function", J. Exp. Med. Vol. 193, No. 4, pp 417-426, 2001	
		MICHAEL KARIN, et al. "Phosphorylation Meets Ubiquitination: The Control of NF- $\kappa$ B Activity", Ann. Rev. Immunology. Vol. 18, pp 621-663, 2000	
		AKEMI MATSUSHIMA, et al. "Essential Role of Nuclear Factor (NF)- $\kappa$ B-inducing Kinase and Inhibitor of $\kappa$ B (I $\kappa$ B) Kinase $\alpha$ in NF- $\kappa$ B Activation through Lymphotoxin Beta Receptor, but Not through Tumor Necrosis Factor Receptor I", J. Exp. Med. Vol. 193, No. 5, pp. 631-636, 2001	
		INDER M. VERMA, et al. "Rel/NF- $\kappa$ B/I $\kappa$ B Family: Intimate tales of association and dissociation", Genes & Development, Vol. 9, pp 2723-2735, 1995	
		CONRAD C. BLEUL, et al. "A Highly Efficacious Lymphocyte Chemoattractant, Stromal Cell-derived Factor 1 (SDF-1)", J. Exp. Med., Vol. 184, pp 1101-1109, 1996	
TCG		VIGO HEISSMEYER, et al. "NF- $\kappa$ B p105 is a target of I $\kappa$ B kinases and controls signal induction of Bcl-3-p50 complexes", The EMBO Journal, Vol. 18, No. 17, pp 4766-4778, 1999	

Examiner Signature	/Terra Cotta Gibbs/	Date Considered	01/31/2007
--------------------	---------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/730,614		
		Filing Date	12/08/2003		
		First Named Inventor	Jun Li		
		Art Unit	1635		
		Examiner Name	GIBBS, Terra C.		
Sheet	9	of	9	Attorney Docket Number	9/263

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
TCG		GIICHI TAKAESU, et al. "TAK1 is Critical for IκB Kinase-mediated Activation of the NF-κB Pathway", J. Mol. Biol., Vol. 326, pp 105-115, 2003	
TCG		WATHELET, et al. "2-Aminopurine selectively blocks the transcriptional activation of cellular genes by virus, double-stranded RNA and Interferons in Human cells", European Journal of Biochemistry, 1989, Vol. 184, pp 503-509	
TCG		MANTHEY, et al. "SB202190, a selective inhibitor of p38 mitogen-activated protein kinase, is a powerful regulator of LPS-induced mRNAs in monocytes", Journal of Leukocyte Biology, 1998, Vol. 64, pp 409-417	

Examiner Signature	/Terra Cotta Gibbs/	Date Considered	01/31/2007
--------------------	---------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.